This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Optimizing the Efficacy–Toxicity Paradigm in Pediatric Oncology: A Narrative Review of Immunotherapy and Survivorship Outcomes
by
, ,
Zaure Dushimova
1
,
Timur Saliev
2,*,
Aigul Bazarbayeva
3,
Kymbat Karimova
3,
Abay Kussainov
3 and
Ildar Fakhradiyev
2,4 1
Department of Fundamental Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
2
Institute for Fundamental and Applied Medical Research, S.D. Asfendiyarov Kazakh National Medical University, Tole Bi Street 94, Almaty 050000, Kazakhstan
3
Scientific Centre of Pediatric and Pediatric Surgery, Al-Farabi Avenue 146, Almaty 050060, Kazakhstan
4
College of Medicine, Korea University, Seoul 02841, Republic of Korea
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2026, 33(5), 298; https://doi.org/10.3390/curroncol33050298
Submission received: 30 March 2026
/
Revised: 13 May 2026
/
Accepted: 18 May 2026
/
Published: 20 May 2026
(This article belongs to the Special Issue Quality of Life and Management of Pediatric Cancer)
Simple Summary
At present, nearly 80% of children diagnosed with cancer are now cured, representing remarkable therapeutic progress. Yet most survivors face lifelong health challenges, including heart damage, infertility, secondary cancers, and cognitive impairment. This review examines how novel immunotherapies, such as blinatumomab for leukemia and CAR T-cells for neuroblastoma, dramatically improve survival while introducing distinct toxicities. A key finding is that treatment timing critically influences outcomes: earlier use of these therapies yields significantly better results. These insights underscore that true success in pediatric oncology extends beyond achieving a cure to minimizing treatment-related harm, ensuring that children not only survive but thrive long after therapy ends.
Abstract
Background: Childhood cancer survival now approaches 80% in high-income countries, yet most survivors face lifelong toxicity. This review examines the interplay between treatment efficacy, relapse prevention, and therapy-related complications. Methods: Narrative synthesis of landmark pediatric oncology trials (2000–2026), including AALL1731 (blinatumomab), ELIANA/PLAT-02 (CAR T-cell), and GD2-CART01 (neuroblastoma), with comparative analysis of efficacy and toxicity. Results: In AALL1731, adding blinatumomab to chemotherapy improved 3-year disease-free survival from 87.9% to 96.0% (HR = 0.39, 95% CI: 0.27–0.56, p < 0.001), but increased sepsis from 5.1% to 14.8%. Comparison between AALL1731 (front-line blinatumomab) and ELIANA (CAR T-cell in relapsed disease) reveals that earlier immunotherapy deployment yields better outcomes: 96% DFS vs. 48% 3-year EFS, respectively. In GD2-CART01, early use (after 1–2 prior lines) achieved 89% 5-year survival vs. 43% with delayed use (HR = 0.31). Approximately 95% of survivors experience ≥1 late effect, with 60–90% carrying chronic conditions into adulthood. Conclusions: Immunotherapy transforms outcomes, but timing is critical, as earlier deployment dramatically improves survival. Toxicity remains pervasive, requiring systematic mitigation strategies.
Keywords:
pediatric; leukemia; immunotherapy; relapse prevention; blinatumomab; neuroblastoma
